PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE
Clinical safety rating: safe
CNS depressants may enhance sedative effects Can cause respiratory depression in children and extrapyramidal symptoms.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
| Metabolism | Phenylephrine undergoes hepatic metabolism by monoamine oxidase (MAO); promethazine is extensively metabolized in the liver via CYP2D6 and other pathways. |
| Excretion | Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%). |
| Half-life | Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment). |
| Protein binding | Phenylephrine: 95% primarily to albumin. Promethazine: 93% primarily to albumin. |
| Volume of Distribution | Phenylephrine: 0.3-0.5 L/kg (distributes into extracellular fluid; does not cross blood-brain barrier significantly). Promethazine: 5-15 L/kg (large distribution due to high lipophilicity; extensive tissue binding including CNS). |
| Bioavailability | Phenylephrine: oral ~38% (due to first-pass metabolism), IM ~100%, IV 100%. Promethazine: oral ~25% (extensive first-pass), IM ~70-80%, IV 100%, rectal ~15-25%. |
| Onset of Action | Phenylephrine: IV (immediate), IM (10-15 min), oral (15-20 min), topical (vasoconstriction within 5 min). Promethazine: IM (20 min), IV (3-5 min), oral (20 min), rectal (20-30 min). |
| Duration of Action | Phenylephrine: IV (15-20 min), IM (30-60 min), oral (1-2 hours), topical nasal decongestion (4 hours). Promethazine: IM/IV (2-8 hours depending on effect; antiemetic 4-6 hours, sedation up to 8 hours), oral (6-12 hours). |
| Molecular Weight | Phenylephrine HCl: 203.67 Da; Promethazine HCl: 320.88 Da; combination: not applicable. |
| Action Class | Antihistamine / Antiemetic |
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
| Dosage form | SYRUP |
| Renal impairment | Not specifically defined. Use with caution in severe renal impairment; no dose adjustment recommended. |
| Liver impairment | Child-Pugh A and B: Use with caution. Child-Pugh C: Avoid use due to promethazine metabolism. |
| Pediatric use | Not established for combination; individual components: Phenylephrine IV 5-20 mcg/kg/dose; Promethazine: not recommended in children <2 years, 0.25-1 mg/kg/dose IM/IV. |
| Geriatric use | Elderly patients may be more sensitive to anticholinergic and hypotensive effects. Use lower initial doses and monitor closely. |
| 1st trimester | Phenylephrine: Limited data; may cause reduced uterine blood flow; use only if clearly needed. Promethazine: Contraindicated in first trimester due to risk of teratogenicity (retroperitoneal fibrosis, skeletal malformations); avoid use. |
| 2nd trimester | Phenylephrine: May cause reduced placental perfusion; use with caution. Promethazine: Use only if clearly needed; avoid in late pregnancy near delivery due to possible extrapyramidal effects in neonate. |
| 3rd trimester | Phenylephrine: Risk of fetal hypoxia due to vasoconstriction; avoid near term. Promethazine: Avoid use near term; may cause respiratory depression, extrapyramidal symptoms in neonate, and prolong labor. |
Clinical note
CNS depressants may enhance sedative effects Can cause respiratory depression in children and extrapyramidal symptoms.
| FDA category | Animal |
| Placental transfer | Both drugs cross the placenta. Phenylephrine: Transfers but limited data; may cause fetal vasoconstriction. Promethazine: Readily crosses placenta; associated with neonatal respiratory depression and extrapyramidal signs if used near term. |
■ FDA Black Box Warning
Respiratory depression risk in children under 2 years; contraindicated in this age group. Not recommended for use in children under 6 years.
| Common Effects | nausea/vomiting |
| Serious Effects | Respiratory depression (especially in children), Severe hypotension or hypertension, Arrhythmias (e.g., tachycardia, bradycardia), Neuroleptic malignant syndrome, Extrapyramidal symptoms (dystonia, akathisia, tardive dyskinesia), Seizures, Agranulocytosis, Cholestatic jaundice, Anaphylaxis, Injection site reactions (e.g., necrosis, gangrene with IV use) |
Hypersensitivity to phenylephrine, promethazine, or any componentPheochromocytomaSevere hypertension (for phenylephrine component)History of obstructive sleep apnea or severe respiratory depression (promethazine component)Use of MAO inhibitors within 14 days (phenylephrine component)Children under 2 years of age (due to risk of fatal respiratory depression from promethazine)Comatose or severely depressed states (promethazine)First trimester of pregnancy (promethazine teratogenicity risk)
| Precautions |
Loading safety data…
| Breastfeeding | Phenylephrine: Excreted in breast milk in small amounts; likely compatible but monitor infant for hypertension or irritability. Promethazine: Excreted in breast milk; may cause sedation, respiratory depression, or impaired platelet aggregation in nursing infant. Avoid use in breastfeeding when possible; if used, monitor infant for drowsiness and respiratory issues. |
| Lactation Rating | L3 (Moderately Safe) for phenylephrine; L4 (Possibly Hazardous) for promethazine. Combined rating: L4. |
| Teratogenic Risk | First trimester: Phenylephrine may reduce uterine blood flow; promethazine is not associated with major malformations but caution due to anticholinergic effects. Second/third trimester: Phenylephrine may cause fetal hypoxia; promethazine risk of neonatal respiratory depression if used near term. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and fetal heart rate. Assess for uterine contractions and signs of fetal distress. |
| Fertility Effects | Phenylephrine: No known significant impact on fertility. Promethazine: May cause menstrual irregularities or transient infertility due to hyperprolactinemia. |
| May cause respiratory depression, especially in children; avoid use in children under 6. Use with caution in patients with asthma, COPD, sleep apnea, or other respiratory conditions. May cause sedation and impair mental/physical abilities. Risk of CNS stimulation, including seizures. May cause hypotension or hypertension. Monitor for extrapyramidal symptoms with prolonged use. Use in elderly may increase risk of confusion, dizziness, and falls. |
| Food/Dietary | Avoid alcohol due to additive sedative effects. No specific food interactions are known, but taking with a meal may reduce GI upset. Patients on MAO inhibitors should avoid tyramine-rich foods (aged cheeses, cured meats) as phenylephrine may precipitate hypertensive crisis. |
| Clinical Pearls | Phenylephrine is an α-1 adrenergic agonist used for decongestion; promethazine is a phenothiazine antihistamine with antiemetic and sedative properties. Monitor for anticholinergic effects (dry mouth, blurred vision, urinary retention) and extrapyramidal symptoms (dystonia, akathisia) due to promethazine. Avoid use in children <2 years due to risk of respiratory depression. Phenylephrine may elevate blood pressure; use cautiously in hypertension, hyperthyroidism, and narrow-angle glaucoma. Promethazine may cause photosensitivity and prolong QTc interval. |
| Patient Advice | Avoid alcohol and CNS depressants as they increase sedation and dizziness. · Do not drive or operate heavy machinery until you know how this medication affects you. · Report any severe drowsiness, confusion, difficulty urinating, or muscle stiffness to your healthcare provider. · Take with food if gastrointestinal upset occurs. · Avoid prolonged sun exposure and use sunscreen as promethazine may increase sensitivity to sunlight. · Do not exceed recommended dose; high doses of phenylephrine can cause dangerously high blood pressure. |